mug180 Antibody

What is TMEM180 and why is it a target for antibody development?

TMEM180 is a novel colorectal cancer (CRC)-specific molecule identified as an eleven-pass transmembrane protein that functions as a cation symporter. It represents an attractive therapeutic target because of its specific expression pattern - highly expressed in colorectal cancer tissues while showing minimal expression in normal major organs. Unlike other therapeutic targets such as EGFR (targeted by cetuximab), TMEM180 demonstrates significantly lower expression in healthy tissues including skin, brain, liver, and colon, potentially reducing treatment-related side effects while maintaining therapeutic efficacy .

How does TMEM180 expression compare between colorectal cancer and normal tissues?

Comprehensive expression analyses between pure normal mucoepithelial cells and CRC cell lines revealed that TMEM180 is highly expressed in five colorectal cancer cell lines (SW480, LoVo, DLD-1, HT-29, and HCT116) but shows negligible expression in normal colonocytes. This expression pattern was validated through multiple methods:

• Quantitative RT-PCR demonstrated high TMEM180 expression in CRC tissue samples

• In situ hybridization confirmed the cancer-specific expression pattern

• Immunohistochemistry showed that approximately 24.3% of CRC tissues (9/37) were strongly TMEM180-positive, and 43.2% (16/37) were weakly positive

• Importantly, immunohistochemical staining with anti-TMEM180 antibody showed no detectable expression in major normal organs including brain, heart, lung, liver, kidney, colon, and skin

What methods are used to detect TMEM180 expression in research settings?

Several complementary methodologies have been established for detecting TMEM180 expression:

• Quantitative RT-PCR (qPCR): For mRNA expression analysis in cell lines and tissue samples

• In situ hybridization (ISH): For visualization of TMEM180 mRNA in tissue sections

• Immunohistochemistry (IHC): Using anti-TMEM180 monoclonal antibodies to detect protein expression in fixed tissues

• Flow cytometry: For analyzing TMEM180 expression on live cells

• ELISA: Particularly useful for detecting TMEM180-positive exosomes

• Western blot analysis: For protein level quantification in cell lysates

• Immunogold electron microscopy: Specifically for visualizing TMEM180 on exosomes

How are anti-TMEM180 antibodies produced for research purposes?

The production of anti-TMEM180 antibodies involves several sophisticated steps:

• Initial antibody generation: Hybridoma cells are established using myeloma cells (p3×63) and lymph-node cells from rats immunized with either:

  • Recombinant human extradomain (355–400 aa) of TMEM180, or

  • TMEM180-positive tumor exosomes purified from the culture supernatant of DLD-1-OE cells

• Antibody conversion: The initial rat IgM antibodies can be humanized by cloning the heavy-chain variable and kappa light-chain variable-region cDNAs into human IgG1 expression vectors

• Stable production: The vectors are transfected into CHO cells to establish stable clones producing humanized IgG antibodies against TMEM180

How does hypoxia affect TMEM180 expression and what are the research implications?

The TMEM180 promoter region contains ten hypoxia-responsive element (HRE) consensus sequences, making it responsive to low-oxygen conditions. Research has demonstrated that SW480 colorectal cancer cells significantly upregulate TMEM180 expression under hypoxic conditions. This hypoxia-inducible characteristic has important research implications:

• It may explain the heterogeneous expression of TMEM180 within tumors, with higher expression expected in hypoxic regions

• It suggests TMEM180 might play a role in the adaptive response of cancer cells to hypoxic microenvironments

• It provides a potential mechanism to enhance target expression for therapeutic antibodies by manipulating oxygen levels in experimental models

• The correlation between hypoxia-inducible factor 1-alpha (HIF-1α) and TMEM180 expression offers a mechanistic pathway for further investigation

What evidence supports TMEM180's role in cancer stemness and tumor microenvironment interactions?

Multiple lines of evidence suggest TMEM180 may function as a cancer stem cell marker with significant implications for tumor-stroma interactions:

• TMEM180 expression positively correlates with anchorage-independent colony formation and tumorigenesis in SW480 cells

• TMEM180-positive cells are preferentially located at the tumor-stroma interface characterized by αSMA-positive fibroblasts, which is known as the tumor niche

• Some clusters of TMEM180-positive cells adjacent to this niche are also integrin α6-positive, another marker associated with stemness

• TMEM180 may be involved in the uptake or metabolism of glutamine and arginine, which are amino acids crucial for tumor growth and proliferation

• Knockdown of TMEM180 in SW480 cells impairs their ability to grow in serum-free medium containing glutamine and arginine

What is the significance of TMEM180 on tumor-derived exosomes and how can researchers isolate and study them?

The discovery that TMEM180 is present on tumor-derived exosomes opens new avenues for both research and potential liquid biopsy applications. Researchers can isolate and study TMEM180-positive exosomes using this protocol:

• Exosome isolation:

  • Plate 6.8 × 10^6 DLD-1 cells on 15-cm dishes and grow overnight

  • Deplete FBS-supplemented medium by washing twice with PBS

  • Incubate cells with serum-free culture medium (30 ml/dish) for 24 hours

  • Collect and filter the supernatant through a 0.22-μm filter

  • Store the exosome-containing supernatant at 4°C with protease inhibitors

• Verification methods:

  • Immunogold electron microscopy using anti-TMEM180, anti-CD9, or anti-CD63 antibodies

  • Sandwich ELISA with anti-TMEM180 mAb or anti-CD9 mAb as capture antibodies and HRP-labeled anti-TMEM180 mAb as detection antibody

The presence of TMEM180 on exosomes suggests potential roles in intercellular communication within the tumor microenvironment and offers opportunities for developing exosome-based diagnostics .

How does the mechanism of action of anti-TMEM180 antibody differ from other therapeutic antibodies for colorectal cancer?

The anti-TMEM180 antibody represents a novel approach to targeting colorectal cancer with several distinguishing features compared to established therapeutics like cetuximab (anti-EGFR):

• Target specificity: TMEM180 shows higher cancer specificity than EGFR, which is expressed in several normal tissues including skin (leading to cetuximab's common skin toxicity)

• Tumor microenvironment interaction: Anti-TMEM180 antibody targets cells at the tumor-stroma interface, potentially disrupting critical microenvironmental interactions

• Metabolic function: By targeting a presumed cation symporter involved in amino acid metabolism, anti-TMEM180 antibody may directly impact cancer cell nutrient acquisition

• Exosome targeting: The presence of TMEM180 on tumor exosomes suggests the antibody might interfere with exosome-mediated intercellular communication

• Reduced off-target effects: Immunohistochemistry studies demonstrate minimal TMEM180 expression in major organs, contrasting with EGFR's widespread expression pattern in normal tissues

What experimental controls should be included when evaluating TMEM180 antibody specificity?

Rigorous experimental design for TMEM180 antibody validation requires several controls:

• Negative cell lines: Hematopoietic cells that do not express TMEM180 should be used to confirm antibody specificity

• TMEM180 knockdown controls: TMEM180 gene knockdown cell lines (like the KD1 and KD2 SW480 variants described in the literature) provide essential negative controls

• Overexpression systems: Cell lines engineered to overexpress TMEM180 serve as positive controls

• Normal tissue panels: A panel of normal tissues (brain, heart, lung, liver, kidney, colon, and skin) should be used to confirm minimal cross-reactivity

• Isotype controls: Appropriate isotype-matched control antibodies must be included in all flow cytometry and immunohistochemistry experiments

• Validation across methods: Correlation between protein detection (by antibody) and mRNA expression (by qPCR or ISH) strengthens specificity claims

What are the recommended protocols for immunohistochemistry using anti-TMEM180 antibodies?

For optimal immunohistochemical detection of TMEM180, the following protocol is recommended based on published research:

• Specimen preparation:

  • Fix tissues appropriately (4% PFA for frozen sections)

  • For formalin-fixed paraffin-embedded tissues, perform antigen retrieval as needed

• Blocking and antibody incubation:

  • Block with 5% skim milk in PBS for 1 hour at room temperature

  • Incubate with HRP-conjugated anti-TMEM180 mAb for 1 hour at room temperature

  • Wash thoroughly with PBS

• Detection and visualization:

  • Visualize using DAB (3,3'-diaminobenzidine)

  • Counterstain with hematoxylin

  • For fluorescence detection, use anti-HRP antibody conjugated with fluorophores (e.g., Alexa Fluor 647)

• Assessment:

  • Score TMEM180 expression as negative, weakly positive, or strongly positive

  • Compare with established markers (such as EGFR) using the same scoring system

How can researchers establish TMEM180 knockdown models for functional studies?

The establishment of TMEM180 knockdown models is critical for functional studies investigating the biological roles of this molecule:

• Gene silencing approaches:

  • Design specific shRNA or siRNA targeting TMEM180 mRNA

  • Validate knockdown efficiency at both mRNA (qPCR) and protein (Western blot, flow cytometry) levels

  • Establish stable knockdown cell lines through antibiotic selection

• Functional validation:

  • Assess growth characteristics in both standard and nutrient-restricted conditions

  • Evaluate colony formation in soft agar to assess anchorage-independent growth

  • Test tumor formation capacity in xenograft models

• Phenotypic analysis:

  • Examine glutamine and arginine uptake using radioactively labeled amino acids

  • Assess metabolic profiles using techniques like Seahorse analysis

  • Investigate cell surface marker expression changes by flow cytometry

What are the prospects for developing TMEM180 antibody-drug conjugates (ADCs)?

The high specificity of TMEM180 expression in colorectal cancer and its minimal presence in normal tissues makes it an attractive target for antibody-drug conjugate (ADC) development:

• Internalization potential: As a transmembrane protein, TMEM180 may undergo receptor-mediated endocytosis upon antibody binding, facilitating the delivery of conjugated cytotoxic payloads

• Conjugation strategies: Research could explore various linker chemistries and cytotoxic payloads to optimize ADC efficacy and stability

• Bystander effect utilization: ADCs with membrane-permeable metabolites could target both TMEM180-positive cells and adjacent TMEM180-negative tumor cells

• Combination approaches: TMEM180 ADCs might be combined with immune checkpoint inhibitors or conventional chemotherapies to enhance efficacy

• Target population enrichment: The correlation between TMEM180 expression and cancer stemness suggests ADCs might preferentially eliminate tumor-initiating cells

How might TMEM180 antibodies be used for imaging applications in research and clinical settings?

TMEM180 antibodies offer promising applications for molecular imaging in both research and potential clinical contexts:

• Preclinical imaging:

  • Fluorescently labeled anti-TMEM180 antibodies for intravital microscopy

  • Radiolabeled antibodies for PET/SPECT imaging of tumor xenografts

  • Near-infrared fluorescence imaging for intraoperative visualization in animal models

• Translational potential:

  • Radiolabeled antibody fragments (Fab, scFv) for improved tumor penetration and faster clearance

  • Immuno-PET imaging for patient stratification based on TMEM180 expression

  • Intraoperative guidance using fluorescent anti-TMEM180 antibodies for surgical resection

• Methodological considerations:

  • Optimization of antibody fragments versus full IgG for imaging applications

  • Evaluation of different conjugation methods for various imaging modalities

  • Assessment of minimum detectable expression levels in heterogeneous tumors

What is the research potential for exploring TMEM180's role in nutrient transport and cancer metabolism?

The identification of TMEM180 as a putative cation symporter opens significant research avenues related to cancer metabolism:

• Transport function characterization:

  • Detailed investigation of substrate specificity using radioactively labeled compounds

  • Electrophysiological studies to characterize transport kinetics

  • Structure-function analyses to identify critical domains for transport activity

• Metabolic impact assessment:

  • Metabolomic profiling of TMEM180 knockdown versus wildtype cells

  • Isotope tracing experiments to track nutrient utilization patterns

  • Analysis of metabolic vulnerabilities created by TMEM180 inhibition

• Therapeutic implications:

  • Development of small molecule inhibitors targeting TMEM180 transport function

  • Investigation of synergistic effects between TMEM180 inhibition and existing metabolic therapies

  • Exploration of synthetic lethal interactions with other metabolic pathway alterations

What factors influence the heterogeneous detection of TMEM180 in tumor samples?

TMEM180 detection in tumor samples can be variable, and researchers should consider several factors that contribute to this heterogeneity:

• Hypoxic regulation: Since TMEM180 expression is regulated by hypoxia, variation in oxygen tension across tumor regions will affect expression levels

• Tumor cell differentiation: TMEM180 expression may correlate with differentiation status and stemness features of cancer cells

• Technical considerations:

  • Fixation methods and duration can affect epitope preservation

  • Antibody concentration and incubation conditions require optimization

  • Detection systems (chromogenic vs. fluorescent) have different sensitivity levels

• Biological factors:

  • Proximity to stromal elements influences TMEM180 expression

  • Cell cycle stage may affect expression levels

  • Prior treatments may alter expression patterns

How can researchers address false-positive and false-negative results when using TMEM180 antibodies?

To minimize false results when working with TMEM180 antibodies, researchers should implement these quality control measures:

• For minimizing false positives:

  • Use multiple antibody clones targeting different epitopes

  • Include appropriate isotype controls

  • Perform peptide blocking experiments to confirm specificity

  • Validate with orthogonal methods (e.g., mRNA expression)

• For minimizing false negatives:

  • Optimize antigen retrieval for FFPE samples

  • Use signal amplification systems for low-expressing samples

  • Consider the impact of sample age and storage conditions

  • Test multiple antibody concentrations to determine optimal sensitivity

• Validation approaches:

  • Compare results across complementary techniques (IHC, flow cytometry, Western blot)

  • Include known positive and negative controls in each experiment

  • Consider TMEM180 expression induction (e.g., hypoxia) as positive control

What are the critical parameters for successful exosome isolation and TMEM180 detection?

Working with TMEM180-positive exosomes requires attention to several critical parameters:

• Exosome isolation optimization:

  • Cell density and culture conditions significantly impact exosome yield

  • Serum-free conditions are essential to avoid contamination with serum-derived exosomes

  • Filtration and purification steps must be carefully standardized

  • Protease inhibitors are crucial to preserve TMEM180 integrity

• Detection considerations:

  • Fresh preparation is preferable, as storage can affect exosome integrity

  • Electron microscopy requires careful sample preparation to preserve morphology

  • ELISA sensitivity depends on antibody pair selection and optimization

  • Western blotting for exosomal TMEM180 requires concentrated samples

• Quality control measures:

  • Confirm exosome identity with established markers (CD9, CD63)

  • Verify size distribution using nanoparticle tracking analysis

  • Assess purity through protein-to-particle ratio measurements

  • Include exosomes from TMEM180-negative cells as controls

Supplemental Data Table: TMEM180 Expression Comparison in Normal and Cancerous Tissues